Doximity Inc
Company Overview: Doximity, Inc. (NYSE: DOCS) provides a digital platform for United States (U.S) medical professionals. The Company's cloud-based platform provides tools to its members, which help them to collaborate with colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with medical news and research, and manage careers.
As per our previous US Earning Hunter report published on ‘DOCS’ on 08th September 2023, Kalkine provided a ‘Buy’ stance on the stock at USD 23.15 based on “decent fundamentals, healthy top-line results, other key financial highlights, earning hunter score, and key risks associated with the business” and the stock price has now moved by ~27.60% since then and the price has achieved resistance 1 and resistance 2.
Noted below are the details of support and resistance levels provided in our previous report:
DOCS’s Daily Chart
Considering the resistance around the range of USD 30.00 – USD 32.00, resistance 1 and resistance 2 levels attainment, current trading levels, risks associated, and volatile market conditions on the back of higher interest rates, an ‘Unattractive’ rating is assigned to the “DOCS” at the closing market price of USD29.54 (as of 12 January 2024).
Note: This report may be updated with details around fundamental and technical analysis, price/ chart in due course, as appropriate
Note 1: Past performance is not a reliable indicator of future performance.
Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is January 12, 2024. The reference data in this report has been partly sourced from REFINITIV.
Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.
Note 4: Target Price refers to a price level that the stock is expected to reach as per the relative valuation method and or technical analysis taking into consideration both short-term and long-term scenarios.
Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the New York Stock Exchange (NYSE), NASDAQ Capital Markets (NASDAQ), and or REFINITIV. Typically, all sources (NYSE, NASDAQ, or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.’